Long-awaited FDA guidance addresses one key obstacle to value-based contracting

As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical companies. These innovative payment arrangementscan help deliver savings for patients, private payors and the government in addition to the potential for better clinical outcomes. Recent, long-awaited final guidance from the U.S. Food and Drug Administration provides much-needed clarity in engaging in the communications that facilitate these arrangements.

Source: The Catalyst - June 19, 2018 Category: Pharmaceuticals Authors: Jim C. Stansel Source Type: news